Search PubMed⌕ Search

Biomedical subjects

J Roy

Publications and source records attributed to J Roy.

At least 181 records · Page 10Linked to original sources
PubMed1977

[Binding sites for 3H-Leu-enkephalin in rat straitum].

The binding of 3H-Leu-Enkephalin to a particulate fraction from Rat striatum has been investigated in the presence of 20 mum bacitracin which prevents its hydrolysis. After deduction of a low-affinity, "non-saturable" component, the saturation kinetics at equilibrium provide evidence for two distinct saturable sites. The first exhibits Michaelis kinetics with a Kd value of 2.7 +/- 0.1 nM; both morphine and naloxone compete with the binding of 3H-Leu-Enkephalin on this site but not on the second one. The marked decrease in binding of 3H-Leu-Enkephalin observed in the presence of high concentration of sodium ions indicates that these two pentapeptides have the same properties as morphinomimetic analgesics. Taken together, these data indicate that the first site is identical to the "opiate receptor", while the nature of the second saturable site remains to be established.

Analgesics↗
PubMed1976

Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.

The proline residue in position 7 of oxytocin occupies one of the four corner positions in the two beta turns proposed for the preferred conformation of the pituitary hormone. It has been suggested that synthetic modifications of the residues in these corner positions will yield analogues in which one or more of the biological activities of the parent hormone is highly accentuated in terms of potency relative to other activities. In a continued effort to test this hypothesis the following analogues of oxytocin were prepared: [7-glycine]oxytocin, [1-beta-mercaptopropionic acid,7-glycine]oxytocin, [7-alanine]oxytocin, and [1-beta-mercaptopropionic acid,7-alanine]oxytocin. These peptides were found to possess the following specific activities, respectively: rat uterotonic, 65 +/- 2, 355 +/- 3, 22 +/- 1, 123 +/- 4; avian vasodepressor, 5.3 +/- 0.8, 17 +/- 0.4, 4.8 +/- 0.1, 9.8 +/- 0.5; rat antidiuretic, less than0.01, 0.062, 0.081 +/- 0.01, 0.17 +/- 0.01; rat pressor, 0.3, 0.5, 0.4, 0.5 unit/mg. Thus the analogues retain high uterotonic activity but exhibit strongly diminished renal and vascular activities relative to oxytocin. Especially noteworthy is [1-beta-mercaptopropionic acid,7-glycine]oxytocin with its high uterotonic activity but very low antidiuretic and pressor activities. The activity profile of this analogue combined with the fact that it is only slowly enzymatically degraded warrants further investigations of this peptide for clinical applications.

Animals↗
PubMed1976

Importance of the third amino acid residue of oxytocin for its action on isolated rat uterus: study of relationship between hormone conformation and activity.

In a continued effort to relate the three-dimensional structure of a peptide hormone to its biological activity, the dose-response relationships of [3-phenylalanine] oxytocin (oxypressin), with an aromatic amino acid residue in position 3, and [3-beta-cyclohexylalanine]oxytocin, with an aliphatic amino acid residue to position 3, were determined in the rat uterine assay in vitro and compared to that of oxytocin. Oxypressin has not only a lower affinity for the smooth muscle receptor than the natural hormone, but also a decreased maximal response (efficacy). [3-beta-Cyclohexylalanine]oxytocin exhibits an even lower affinity than oxypressin, but retains the same maximal response as oxytocin. A reorientation of the tyrosine sidechain, caused by the presence of a neighboring aromatic sidechain in position 3, away from the surface of the 20-membered ring is though to remove the phenolic hydroxyl group from its optimal position in the "active center" of oxytocin and give rise to the reduced efficacy of oxypressin.

Animals↗
PubMed1975

Oxytocin analogs with substitutions in postions 3 and 4.

Synthesis and biological properties are reported for some analogs of oxytocin with replacements of the isoleucine residue in position 3, i.e., (3-proline)oxytocin and(3-D-alanine)oxytocin, and the glutamine residue in position 4, i.e., (4-D-alanine)-oxytocin and (4-D-leucin)oxytocin. (3-Proline)oxytocin exhibited smaller than0.02 U/MG oxytocic activity, 0.005 plus or minus smaller than 0.001 U/mg rat pressor activity and 0.003 plus or minus 0.0001 U/mg antidiuretic activity. (3-D-Alanine)oxytocin had no agonistic activity in the bioassays tested except for the rat antidiuretic assay (smaller than 0.0005 U/mg). The 4-D-alanine analog showed 0.05 plus or minus 0.003 U/mg oxytocic activity, 0.07 plus or minus 0.01 U/mg avian vasodepressor activity, and smaller than 0.001 U/mg rat antidiuretic activity. (4-D-Leucine)oxytocin possessed 0.001 plus or minus U/mg rat pressor activity, and showed slight inhibitory properties in the oxytocic and avian vasodepressor assays, inhibiting the oxytocin response in the latter assay by about 60% at a girnibe-to-analog ratio of 1:5000. The activity profiles of the analogs are compared to that of oxytocin and are discussed on the basis of the proposed solution conformation of oxytocin.

Alanine↗